Overall, sequencing of BRCA1/2 coding exons identified additional predicted cancer risk mutations in 52 out of 512 (10%) patients with familial and/or an early onset breast/ovarian cancer that were missed using our standard genotyping procedure. This evidence concerns the gene BRCA1 and ovarian carcinoma.